Zoetis Inc. (NYSE:ZTS) Holdings Increased by Retirement Guys Formula LLC

Retirement Guys Formula LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 4.9% during the fourth quarter, Holdings Channel reports. The firm owned 4,238 shares of the company’s stock after purchasing an additional 197 shares during the period. Retirement Guys Formula LLC’s holdings in Zoetis were worth $691,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $33,000. Finally, Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $174.47 on Wednesday. The company’s fifty day moving average is $169.16 and its 200-day moving average is $179.15. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The firm has a market cap of $78.72 billion, a price-to-earnings ratio of 32.80, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Piper Sandler dropped their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $214.00.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.